Thursday, 18 March 2021

AstraZeneca concerns can’t dent Korean partner’s stunning market debut

SK Bioscience saw its shares gain by its 160 per cent daily limit despite concerns over side effects of AstraZeneca Plc’s COVID-19 vaccine.

from Sydney Morning Herald - Latest News https://ift.tt/3tAhqFt
via IFTTT

No comments:

Post a Comment